Download Files:
BML-280
Products Details
Product Description
– BML-280 (VU0285655-1) is a potent and selective phospholipase D2 (PLD2) inhibitor. BML-280 has the ability to prevent caspase-3 cleavage and reduction in cell viability induced by high glucose. BML-280 can be used for rheumatoid arthritis research[1][2].
Web ID
– HY-114095
Shipping
– Room temperature
Applications
– Metabolism-sugar/lipid metabolism
Molecular Formula
– C25H27N5O2
References
– [1]Burkhardt U, et al. Role of phospholipases D1 and 2 in astroglial proliferation: effects of specific inhibitors and genetic deletion. Eur J Pharmacol. 2015 Aug 15;761:398-404. |[2]Tenconi PE, et al. High glucose-induced phospholipase D activity in retinal pigment epithelium cells: New insights into the molecular mechanisms of diabetic retinopathy. Exp Eye Res. 2019 Jul;184:243-257.|[3]Tsai YR, et al. Inhibition of formyl peptide-stimulated phospholipase D activation by Fal-002-2 via blockade of the Arf6, RhoA and protein kinase C signaling pathways in rat neutrophils. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):507-19.
CAS Number
– 1158347-73-9
Molecular Weight
– 429.51
SMILES
– O=C(C1=CC2=CC=CC=C2N=C1)NCCN(CC3)CCC3(N(C4=CC=CC=C4)CN5)C5=O
Clinical Information
– No Development Reported
Research Area
– Cancer; Metabolic Disease; Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– Interleukin Related;Phospholipase;TNF Receptor
Isoform
– CD40;IL-1;IL-8;PLD
Pathway
– Apoptosis;Immunology/Inflammation;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.